3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
69
Recurrence
20
Neoplasms, Plasma Cell
6
Neoplasms
4
Lymphoma
3
Small Cell Lung Carcinoma
2
Waldenstrom Macroglobulinemia
1
Renal Insufficiency
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Kidney Failure, Chronic
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bone Marrow Neoplasms
1
Blast Crisis
1
Interventions
Lenalidomide
2
Dexamethasone
2
Bortezomib
2
darinaparsin
1
carfilzomib
1
belinostat
1
SCIO-469
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Bone Marrow Neoplasms
×
carfilzomib
×
Clear all
NCT03859427
2024-08-13
ARROW2
Amgen
Phase 3
Completed
454 enrolled
24 charts